Screener
RxSight, Inc. RXST EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by RxSight, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: RxSight, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335153
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Unrealized loss on short-term investments | (5) | (146) | (125) | (303) |
| Foreign currency translation gain | 13 | 14 | 13 | 20 |
| Total other comprehensive gain (loss) | 8 | (132) | (112) | (283) |
| Comprehensive loss | $(12,089) | $(11,918) | $(28,093) | $(20,259) |
| Net loss per share: | ||||
| Basic & diluted | $(0.29) | $(0.29) | $(0.68) | $(0.49) |
| Weighted-average shares used in computing net loss per share: | ||||
| Attributable to common stock, basic & diluted | 41,490,889 | 40,743,786 | 41,399,010 | 40,627,363 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is RxSight, Inc.'s EPS (diluted)?
- RxSight, Inc. (RXST) reported EPS (diluted) of -$0.29 in Q2 2026.
- How has RxSight, Inc.'s EPS (diluted) changed year-over-year?
- RxSight, Inc.'s EPS (diluted) decreased by 0.0% year-over-year, from -$0.29 to -$0.29.
- What is the long-term trend for RxSight, Inc.'s EPS (diluted)?
- Over 3 years (2022 to 2025), RxSight, Inc.'s EPS (diluted) has grown at a -26.7% compound annual growth rate (CAGR), from -$2.41 to -$0.95.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about RxSight, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude